Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)‘s stock had its “hold” rating reaffirmed by investment analysts at J P Morgan Chase & Co in a research report issued to clients and investors on Tuesday.
A number of other equities research analysts have also weighed in on REGN. Zacks Investment Research upgraded shares of Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $540.00 price objective for the company in a report on Wednesday, August 9th. Leerink Swann reiterated an “outperform” rating and set a $580.00 price objective (up previously from $573.00) on shares of Regeneron Pharmaceuticals in a report on Wednesday, August 9th. Robert W. Baird lowered shares of Regeneron Pharmaceuticals from a “neutral” rating to an “underperform” rating and set a $408.00 price objective for the company. in a report on Tuesday, August 8th. Goldman Sachs Group, Inc. (The) reiterated a “neutral” rating and set a $472.00 price objective (up previously from $469.00) on shares of Regeneron Pharmaceuticals in a report on Wednesday, August 9th. Finally, Canaccord Genuity set a $522.00 price objective on shares of Regeneron Pharmaceuticals and gave the company a “buy” rating in a report on Monday, August 14th. Four research analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the stock. The company has a consensus rating of “Hold” and an average price target of $488.57.
Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported $4.17 earnings per share for the quarter, beating analysts’ consensus estimates of $2.67 by $1.50. Regeneron Pharmaceuticals had a net margin of 22.05% and a return on equity of 25.58%. The company had revenue of $1.47 billion during the quarter, compared to analyst estimates of $1.36 billion. During the same quarter last year, the business posted $2.82 EPS. The firm’s revenue for the quarter was up 21.2% on a year-over-year basis.
TRADEMARK VIOLATION NOTICE: This story was first posted by Sports Perspectives and is the property of of Sports Perspectives. If you are accessing this story on another website, it was illegally stolen and republished in violation of United States and international trademark and copyright law. The legal version of this story can be accessed at https://sportsperspectives.com/2017/11/02/regeneron-pharmaceuticals-inc-regn-rating-reiterated-by-j-p-morgan-chase-co.html.
In other Regeneron Pharmaceuticals news, major shareholder Sanofi acquired 166,415 shares of the company’s stock in a transaction dated Thursday, August 24th. The shares were acquired at an average cost of $480.93 per share, with a total value of $80,033,965.95. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. Also, SVP Robert E. Landry sold 526 shares of the company’s stock in a transaction on Tuesday, August 8th. The shares were sold at an average price of $472.19, for a total transaction of $248,371.94. Following the completion of the sale, the senior vice president now directly owns 9,099 shares in the company, valued at $4,296,456.81. The disclosure for this sale can be found here. Insiders sold a total of 89,468 shares of company stock worth $42,312,448 over the last ninety days. Insiders own 10.80% of the company’s stock.
Hedge funds have recently added to or reduced their stakes in the company. Fieldpoint Private Securities LLC acquired a new position in shares of Regeneron Pharmaceuticals in the 2nd quarter valued at $130,000. Sterling Investment Advisors Ltd. lifted its stake in shares of Regeneron Pharmaceuticals by 11.2% in the 2nd quarter. Sterling Investment Advisors Ltd. now owns 278 shares of the biopharmaceutical company’s stock valued at $137,000 after purchasing an additional 28 shares during the period. FNY Partners Fund LP lifted its stake in shares of Regeneron Pharmaceuticals by 200.0% in the 2nd quarter. FNY Partners Fund LP now owns 300 shares of the biopharmaceutical company’s stock valued at $147,000 after purchasing an additional 200 shares during the period. Alpha Windward LLC lifted its stake in shares of Regeneron Pharmaceuticals by 0.3% in the 2nd quarter. Alpha Windward LLC now owns 384 shares of the biopharmaceutical company’s stock valued at $189,000 after purchasing an additional 1 shares during the period. Finally, IFP Advisors Inc lifted its stake in shares of Regeneron Pharmaceuticals by 33.2% in the 2nd quarter. IFP Advisors Inc now owns 385 shares of the biopharmaceutical company’s stock valued at $189,000 after purchasing an additional 96 shares during the period. 67.57% of the stock is currently owned by institutional investors and hedge funds.
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.
Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.